Abstract:Over the last 5 years, cytosine base editors (CBEs) have emerged as a promising therapeutic tool for specific editing of single nucleotide variants and disrupting specific genes associated with disease. Despite this promise, the currently available CBE’s have the significant liabilities of off-target and bystander editing activities, in part due to the mechanism by which they are delivered, causing limitations in their potential applications. In this study we engineeredhighly stabilized Cas-embedded CBEs (sCE_CBEs) that integrate several recent advances, andthat are highly expressible and soluble for direct delivery into cells as ribonucleoprotein (RNP) complexes. Our resulting sCE_CBE RNP complexes efficiently and specifically target TC dinucleotides with minimal off-target or bystander mutations. Additional uracil glycosylase inhibitor (UGI) protein in further increased C-to-T editing efficiency and target purity in a dose-dependent manner, minimizing indel formation to untreated levels. A single electroporation was sufficient to effectively edit the therapeutically relevant locus for sickle cell disease in hematopoietic stem and progenitor cells (HSPC) in a dose dependent manner without cellular toxicity. Significantly, these sCE_CBE RNPs permitted for the transplantation of edited HSPCs confirming highly efficient editing in engrafting hematopoietic stem cells in mice. The success of the designed sCBE editors, with improved solubility and enhanced on-target editing, demonstrates promising agents for cytosine base editing at other disease-related sites in HSPCs and other cell types.

Evaluation of DNA minicircles for delivery of adenine and cytosine base editors using activatable gene on "GO" reporter imaging systems

Adenine Base Editing in vivo with a Single Adeno-Associated Virus Vector

Chemical modifications of adenine base editor mRNA and guide RNA expand its application scope

Two Compact Cas9 Ortholog-Based Cytosine Base Editors Expand the DNA Targeting Scope and Applications In Vitro and In Vivo

Precision genome editing using cytosine and adenine base editors in mammalian cells

Direct delivery of stabilized Cas-embedded base editors achieves efficient and accurate editing of clinically relevant targets

Rational Design of Enhanced Nme2Cas9 and Nme2 Cas9 Nucleases and Base Editors

Re-engineering the adenine deaminase TadA-8e for efficient and specific CRISPR-based cytosine base editing

Engineering a Precise Adenine Base Editor with Minimal Bystander Editing.

Cytosine and Adenine Base Editing of the Brain, Liver, Retina, Heart and Skeletal Muscle of Mice Via Adeno-Associated Viruses

Engineering Nme2Cas9 Adenine Base Editors with Improved Activity and Targeting Scope

Adenine transversion editors enable precise, efficient A•T-to-C•G base editing in mammalian cells and embryos

Engineering precise adenine base editor with infinitesimal rates of bystander mutations and off-target editing

TadA reprogramming to generate potent miniature base editors with high precision

Human Cell Based Directed Evolution of Adenine Base Editors with Improved Efficiency

Directed evolution of adenine base editors with increased activity and therapeutic application

Photoactivatable base editors for spatiotemporally controlled genome editing in vivo

CRISPR-Cas9 DNA Base-Editing and Prime-Editing

A precise and efficient adenine base editor

Improving adenine and dual base editors through introduction of TadA-8e and Rad51DBD

ACBE, a new base editor for simultaneous C-to-T and A-to-G substitutions in mammalian systems